Table 3. Proof-of-concept trial: safety & efficacy outcomes at discharge and follow-up.

	Total		Suramin		Non-suramin
Patients treated	n = 60	%	n = 30	%	n = 30	%
Encephalopathic syndrome	7	11.6	4	13.3	3	10
Death during treatment	7	11.6	5a	16.6	2a	6.6
Relapses at discharge	0		0		0
Cure at end of treatment	53	88.3	25	83.3	28	93.3

NOTE:

^atwo patients from Tanzania had an incomplete treatment and died outside the centre after family members took them back to the village to seek local treatment;

^bnot related to HAT (Tanzania).